Comparison of different injection techniques (Genicular nerve block versus Saphenous nerve block), in knee osteoarthritis management.

Study of outcome & efficacy of Genicular Nerve Block versus Saphenous Nerve Block in Osteoarthritis of Knee: A prospective Randomized Controlled Trial - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/02/062520

Enrollment

Registered

2024-02-12

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M170- Bilateral primary osteoarthritis of knee Health Condition 2: M171- Unilateral primary osteoarthritisof knee

Interventions

Intervention1: GENICULAR NERVE BLOCK IN OSTEOARTHRITIS OF KNEE: No pre-medications or sedatives will be administered. Patient will be in the supine position with a pillow under the popliteal fossa to

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age of patients: Between 50 to 75 years. 2. Diagnosed case of Unilateral/Bilateral OA knee by Radiograph (Kellgren & Lawrence Grading more than or equal to 2). 3. Chronic knee pain lasting over 3 months.

Exclusion criteria

Exclusion criteria: 1. Acute knee pain or knee effusion. 2. Any prior knee surgery. 3. History of intraarticular and, or periarticular injection previous 12 weeks. 4. Progressive neurological disease. 5. Vascular disease. 6. Fracture around knee. 7. Psychiatric disorders. 8. Diabetic patients with HbA1c more than 7.0. 9. Signs of Injection site infection. 10. History of Bleeding disorders. 11. History of Hypersensitivity with Steroids & Local Anaesthetic drugs. 12. Patient who refused to participate in study.

Design outcomes

Primary

Measure	Time frame
1.Numeric Pain Rating Scale (NPRS) 2.Knee Injury and Osteoarthritis Outcome Score (KOOS)Timepoint: at 1st, 4th and 8th week interval.	—

Secondary

Measure	Time frame
Post injection complicationsTimepoint: at 1st week interval.	—

Countries

India

Contacts

Public ContactDr.Anil Kumar Gupta

King Georges Medical University, Lucknow-U.P.

ganeshyadav.pmr@gmail.com9457191240

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026